We found that PD-1 inhibition durably induces a pro-inflammatory state within the primary tumor in situ, as evidenced by a sustained increase in the effector T cell phenotype and decreased representation of immunosuppressive regulatory T cell subsets both in TILs and in PBMCs following exposure to nivolumab. Here, PDCD1 is linked to neoplasm.